Suprachoroidal Hemorrhage after XEN Gel Implant Requiring Surgical Drainage

Kevin Wang¹, Jay C Wang², Soshian Sarrafpour³

Received on: 20 August 2021; Accepted on: 06 December 2021; Published on: 30 August 2022

Abstract

Aim: To describe a case of a patient on anticoagulation who underwent XEN45 (XEN) gel stent placement and subsequently developed kissing suprachoroidal hemorrhages (SCHs) requiring surgical drainage. Background: Minimally invasive glaucoma surgery (MIGS) aims to achieve effective control of intraocular pressure (IOP) while minimizing the complications associated with traditional glaucoma surgeries. Rarely, a severe complication of intraocular surgery is SCH, which can result from early postoperative hypotony. The XEN gel stent is a MIGS device that theoretically avoids the risk of hypotony due to its outflow resistance properties. However, cases of SCH associated with XEN gel stents have been reported.

Case description: A monocular 86-year-old Caucasian male with glaucoma and atrial fibrillation on rivaroxaban underwent routine XEN gel stent placement with mitomycin C in his only seeing eye. On postoperative day 3, he presented with severe eye pain and worsening vision. He was found to have a SCH that gradually progressed to kissing suprachoroidals that required surgical drainage. After extensive discussion, the decision was made to hold the patient’s rivaroxaban given his monocular status. The patient subsequently had a cerebral vascular accident (CVA) 1 week after drainage, but his symptoms gradually resolved after restarting anticoagulation. Two months after drainage, the patient’s SCH had completely resolved, and he had recovered baseline visual acuity with excellent IOP control-off medications.

Conclusion: This case highlights the importance of quick and appropriate management of complications following glaucoma surgery, as well as discussion with patients regarding risks of treatments and return precautions. It also is a reminder that although many new surgical interventions are "minimally invasive," those like the XEN that are more effective at IOP control may have a similar risk profile to more traditional surgeries like trabeculectomy. As such, risk factors like anticoagulation use and older age should be considered in anticipation of surgical intervention.

Clinical significance: The XEN gel stent is a new surgical option for glaucoma patients that asserts a better safety profile than traditional surgeries like trabeculectomy, but our case of kissing SCHs requiring surgical intervention following XEN placement reminds us that even minimally invasive surgeries can have devastating complications.

Keywords: Anticoagulation, Case report, Cerebral vascular accident, Glaucoma, Hypotony, Kissing suprachoroidal hemorrhage, Minimally invasive glaucoma surgery, Postoperative complications, Surgical drainage, XEN45 gel implant.

© The Author(s). 2022 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Suprachoroidal Hemorrhage after XEN Gel Implant Requiring Surgical Drainage

During surgery, the patient’s left eye was prepped and draped in the usual sterile fashion, and a superior conjunctival peritomy was created in preparation for an ab-externo approach. After adequate anesthesia, the subconjunctival area was carefully dissected posteriorly, and topical mitomycin C 0.4 mg/mL sponges were placed for 2 minutes. The XEN needle was entered 2.5 mm posterior to the limbus and advanced to the limbus. Then the XEN gel stent was deployed into the anterior chamber. The stent was noted to be in proper position with good flow, and the conjunctiva was closed with apical wing sutures. At the end of the case, the anterior chamber was deep and there was noted to be no leakage. Subconjunctival antibiotic and steroid were injected, and topical moxifloxacin, atropine, and prednisolone were started.

On postoperative day 1, IOP in the left eye was 4 mm Hg, BCVA was 20/80, and the anterior chamber remained deep and well-formed. Fundus exam was notable for peripheral choroidal effusions. On postoperative day 2, the patient experienced worsening peripheral shadows over his left temporal field of vision, and dilated fundus exam showed a small superotemporal SCH (Fig. 1). IOP in the left eye at this time was 9 mm Hg, visual acuity was stable, and anterior chamber remained deep. The next morning, he woke up, coughed, and reported sudden-onset 10/10 eye pain and worsening vision. IOP was found to be 41 mm Hg in the left eye, and visual acuity was 20/100. Slit lamp exam showed a markedly shallow anterior chamber with a 1 mm layering hyphema. Fundus exam and B-scan showed a small horseshoe tear nasally and worsened temporal and nasal SCH, so the patient was referred to the retina service.

However, despite medical treatment, progression to kissing choroidals had occurred by postoperative week 1 (Fig. 2A). His visual acuity was at the hand motions level and IOP was 5 mm Hg. Laser barricade of the horseshoe tear was attempted but incomplete. B-scan showed liquefaction of the choroidals (Fig. 2B). Given the presence of kissing SCHs and liquefaction on B-scan, surgical intervention was recommended. After discussion with the patient and his cardiologist, the decision was made to hold his anticoagulation preoperatively given his monocular status. The patient underwent successful external drainage through a single sclerotomy in the superotemporal quadrant 8 mm posterior to the limbus. Retinal cryopexy was also performed under direct visualization to treat the retinal tear.

On postoperative day 1, his IOP was 7 mm Hg off IOP-lowering medications in the left eye and visual acuity was counting fingers. After extensive discussion of the risks and benefits with the patient and his family, the decision was made to continue to hold his rivaroxaban until sustained improvement could be demonstrated given his monocular status. However, 1 week after surgical drainage, the patient presented to the emergency department with left-sided weakness and was found to have a transient ischemic attack (TIA). His anticoagulation was restarted, and fortunately his symptoms gradually improved with physical therapy. By 2 months after SCH drainage, the patient’s vision had improved to 20/40 with resolution of his SCHs (Fig. 3), IOP was well-controlled at 10 mm Hg off all medications, and there had been no further CVA episodes.

Discussion

Recent advances in the development of MIGS procedures have led to the creation of the XEN gel implant, which theoretically minimizes the risk of severe complications like suprachoroidal bleeding. The device has a 45-μm-wide inner lumen and a length of 6 mm, which provides an outflow resistance of 6–8 mm Hg predicted by the Hagen–Poiseuille equation, which theoretically avoids hypotony, thus reducing the risk of SCH.7

Given that the device has been in clinical use for only 5 years, it is still unclear what its exact risk profile is. The patient we report here unfortunately developed severe SCH after XEN placement, most likely due to hypotony and anticoagulation use. There have been three
other cases reported in the literature of SCH occurring in the context of XEN gel stent placement, two of which occurred 2 days after XEN placement and one of which occurred intraoperatively.4–6 One of these cases was complicated by retinal detachment requiring surgical intervention, while the others resolved with observation. Our case is thus the fourth reported case of SCH following XEN gel implant and the first requiring reoperation for kissing SCH.

A unique challenge existed with our case, as the patient had a history of atrial fibrillation and was on anticoagulation at the time of SCH. Stopping anticoagulation in patients with atrial fibrillation can increase the risk of stroke and other thromboembolic events. It is estimated that atrial fibrillation presents up to a 12% risk of ischemic stroke and 17% risk of TIA in patients depending on their CHA2DS2-VASc score.8 This risk is reduced by 80% in patients taking anticoagulation therapy.9,10 It is important that patients on anticoagulation be aware of the risks and benefits of continuing anticoagulation prior to surgical intervention, even for minimally invasive glaucoma surgeries, so that an informed and educated decision can be made. In this case, after extensive discussion, the decision was made to temporarily hold anticoagulation to allow the patient’s SCH to resolve and to prevent further loss of vision in the patient’s only seeing eye. It is known that anticoagulation poses a considerable risk for postoperative suprachoroidal bleeding in glaucoma patients. One study by Law et al. showed an increased risk of hemorrhagic complications during and after glaucoma surgery in patients on anticoagulant or antiplatelet therapy (10.1% in patients on anticoagulation or antiplatelets vs 3.7% in controls).11 Other studies have also found that anticoagulation is a significant risk factor for delayed SCH in glaucoma surgery, with nonvalved tube shunts showing the highest rates of SCH.12,13 Furthermore, there have been cases of spontaneous SCH in patients taking anticoagulants.14 Fortunately, with quick and appropriate diagnosis and management, this patient was able to recover his vision, obtain excellent IOP control-off all medications, and recover from his CVA.

**Conclusion**

This case highlights the importance of quick and appropriate management of complications following glaucoma surgery, as well as discussion with patients regarding risks of treatments and return precautions. It also is a reminder that although many new surgical interventions are “minimally invasive,” those like the XEN that are more effective at IOP control may have a similar risk profile to more traditional surgeries like trabeculectomy. Thus, risk factors such as anticoagulation use should be considered in anticipation of surgical intervention.

**Clinical Significance**

The XEN gel stent is a new surgical option for glaucoma patients that claims to have a better safety profile than traditional surgeries such as trabeculectomy, but our case of kissing SCHs requiring surgical intervention following XEN placement is a reminder that even minimally invasive surgeries can have potentially devastating complications.

**References**

1. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
2. Ruderman JM, Harbin TS, Campbell DG. Postoperative suprachoroidal hemorrhage following filtration procedures. Arch Ophthalmol 1986;104(2):201–205. DOI: 10.1001/archoph.1986.01050140055019
3. Wirostko WJ, Han DP, Mieler WF, et al. Suprachoroidal hemorrhage: outcome of surgical management according to hemorrhage severity. Ophthalmology 1998;105(12):2271–2275. DOI: 10.1016/S0161-6420(98)91922-3
4. Liu JC, Green W, Sheybani A, et al. Intraoperative suprachoroidal hemorrhage during XEN gel stent implantation. Am J Ophthalmol 2019;180:1–7. DOI: 10.1016/j.ajo.2019.01.007
5. Prokosch-Willing V, Vossmerbaeumer U, Hoffmann E, et al. Suprachoroidal bleeding after XEN gel implantation. J Glaucoma 2017;26(12):e261–e263. DOI: 10.1097/IJG.0000000000000795
6. Rooney DM, Shadid HR, Siegel LJ, et al. Postoperative complications of ab interno gelatin microstent. J Glaucoma 2019;28(5):e77–e81. DOI: 10.1097/IJG.0000000000001194
7. Sheybani A, Reitsamer H, Ahmed II. Fluid dynamics of a novel micro-fistula implant for the surgical treatment of glaucoma. Invest Ophthalmol Vis Sci 2015;56(8):4789–4795. DOI: 10.1167/iovs.15-16625
8. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33(12):1500–1510. DOI: 10.1093/eurheartj/ehr488
9. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327(20):1406–1412. DOI: 10.1056/NEJM199211232272002
10. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323(22):1505–1511. DOI: 10.1056/NEJM1990071132352013
11. Law SK, Song BJ, Yu F, et al. Hemorrhagic complications from glaucoma surgery in patients on anticoagulation therapy or antiplatelet therapy. Am J Ophthalmol 2008;145(4):736–746. DOI: 10.1016/j.ajo.2007.12.007
12. Tuli SS, WuDunn D, Ciulla TA, et al. Delayed suprachoroidal hemorrhage after glaucoma filtration procedures. Ophthalmology 2001;108(10):1808–1811. DOI: 10.1016/s0161-6420(01)00763-1
13. Jeganathan VS, Ghosh S, Ruddle JB, et al. Risk factors for delayed suprachoroidal haemorrhage following glaucoma surgery. Br J Ophthalmol 2008;92(10):1393–1396. DOI: 10.1136/bjo.2008.141689
14. Hsiao SF, Shih MH, Huang FC. Spontaneous suprachoroidal hemorrhage: case report and review of the literature. Taiwan J Ophthalmol 2016;6(1):36–41. DOI: 10.1016/j.tjo.2014.10.008